Points clés
- 1Two diabetic members cut combined annual spend from $9,400 to $1,130 — 88% — via assistance programmes, biosimilars and unbranded consumables.
- 2The single largest saving came from programmes they already qualified for but had never been told about.
- 3Any insulin change needed intensified glucose monitoring for two weeks and a written hypoglycaemia plan.
- 4The clinically important outcome was ending rationing — the father's HbA1c improved for the first time in two years.
Aperçu du cas
- Profil du patient
- Composite profile — father (type 2) and teenage daughter (type 1)
- Pays
- United States
- Affection
- Insulin-dependent diabetes, two household members
- Médicament
- Insulin glargine, insulin aspart, pen needles, test strips, CGM sensors
Coût occidental
~$9,400 per year
Alternative de référence
~$1,130 per year equivalent basket
Impact
~$8,270 per year
Sur cette page
1The situation
Two insulin-dependent people in one household on a single insurance plan with a substantial deductible. Basal and rapid-acting insulin for both, plus consumables — pen needles, test strips and continuous glucose monitoring sensors for the daughter.
The father had started quietly reducing his own basal dose so his daughter's supply would never be interrupted. His HbA1c had drifted upward over eighteen months and neither he nor his physician had connected that trend to cost.
2The five changes that worked
The diabetes team addressed this across two appointments. Every change was clinical, and glucose monitoring was intensified during the transition.
- 1Enrolled both members in manufacturer insulin cost-cap programmes they were eligible for but had never applied to.
- 2Switched the father's basal insulin to a biosimilar glargine with the endocrinologist's agreement.
- 3Moved the father from prefilled pens to vial-and-syringe delivery after a technique assessment.
- 4Consolidated to 90-day supplies instead of monthly fills.
- 5Sourced pen needles and test strips as unbranded equivalents rather than the branded originals.
| Item | Before | After | Reduction |
|---|---|---|---|
| Insulin glargine (both members) | $3,360 | $410 | 88% |
| Insulin aspart (both members) | $3,120 | $380 | 88% |
| Pen needles and syringes | $540 | $62 | 89% |
| Test strips | $1,180 | $140 | 88% |
| CGM sensors | $1,200 | $138 | 89% |
| Annual total | $9,400 | $1,130 | 88% |
3How the transition was monitored
Insulin changes require close observation. The team set a structured two-week protocol before either member changed product.
- Increased glucose checks for two weeks after each change, including overnight readings.
- A written hypoglycaemia action plan for both members and for the school.
- One change at a time, never both members simultaneously.
- Telephone review at seven days and clinic review at four weeks.
- HbA1c repeated at three months for both.
4Outcome
At the three-month review, the father's HbA1c had improved for the first time in two years — not because of a better insulin, but because he was finally taking the full prescribed dose. His daughter's control remained stable throughout.
The clinically important result was the end of rationing. The financial result made that possible.
5About this case study
This is a composite case study. It illustrates a real, documented price pattern using a representative patient profile rather than a specific identifiable individual. Figures are reference ranges, not quotations, and outcomes vary by person, dose and market.
We publish these because abstract percentages do not communicate what a price gap means to a household. A number like '98% cheaper' is forgettable. A monthly bill that drops from an impossible figure to an affordable one is not.
Nothing here is a recommendation to change your own treatment. Every switch described was made with a prescriber's involvement, and yours should be too.
Jivan publishes pricing and educational information only. Do not start, stop, substitute or re-dose any medicine without a licensed physician's approval.
Ce que montre le jeu de données Jivan
- 58×
- écart moyen de prix Endocrinology
- 77.1%
- des ancres dépassent 10×
- 133×
- plus grand écart documenté
Across our Endocrinology anchors, 35 referenced molecules average a 58× price gap, 77.1% of them are at least 10× cheaper in India, and the widest documented comparison is Levothyroxine at 133×. Endocrinology entries split sharply: consumables (strips, needles) carry the highest percentage discount, while cold-chain biologics carry the highest absolute cash saving per month.
Calculé en direct à partir de 35 anchors
Questions fréquentes
Biosimilars are approved after demonstrating no clinically meaningful differences from the reference product. Switching should be prescriber-led with intensified glucose monitoring for the first weeks.
Usually yes, per unit of insulin. The trade-off is that drawing up requires adequate dexterity, vision and technique, so it needs an assessment before switching.
Contact your prescriber or a pharmacist immediately and say you cannot afford it. Emergency supply mechanisms, manufacturer programmes and clinic samples exist for exactly this situation. Do not ration.
Sources et lectures complémentaires
Chaque fait ci-dessus est traçable vers une source primaire publique. Nous citons les régulateurs et les organismes de santé publique, pas les vendeurs commerciaux.
- 1Diabetes Fact SheetWorld Health Organization
- 2Biosimilar Medicines OverviewEuropean Medicines Agency
- 3Health Costs and Prescription Drug ResearchKFF (Kaiser Family Foundation)
- 4MedlinePlus Drug InformationU.S. National Library of Medicine
Comment cet article a été rédigé
Rédigé et recherché
Pricing Research Editor, Jivan Editorial TeamRelu éditorialement
Editorial Review Board — Jivan
Composite profile assembled from documented price patterns; not a named individual.
Avertissement médical important
Consultez toujours un médecin avant de changer de médicament, de dose ou de marque. Jivan fournit des informations éducatives et tarifaires et ne remplace ni un diagnostic ni les soins d'urgence.